[ad_1]
The prevalence of lung cancer in non-smokers is becoming increasingly recognized in its field. However, progress is lacking in more precise screening and, therefore, in personalized care.
In the November episode of Lungcast, a monthly podcast series from HCPLive and the American Lung Association (ALA), a couple of researchers from the Lung Cancer Interception Research Group sat down with ALA Chief Medical Officer Albert Rizzo, MD, to discuss their team’s work on lung cancer interception.
Among their topics of discussion was the need for progress in identifying and treating nonsmoking lung cancer risk, a priority that has grown to become greater in recent years.
Guests – Avrum Spira, MD, MSc, and Steven Dubinett, MD – explained how advances made in tobacco-related diseases actually inform this next step on their journey towards lung cancer interception, from new technologies to identified immunomodulators. .
“Right now, we know a lot more about smoking-related lung cancer, but over time we will catch up and have something more meaningful for those at risk but don’t smoke,” Dubinett, director of the UCLA Clinical & Translational Science Institute, said. .
Spira, Professor of Medicine, Pathology and Bioinformatics, and Alexander Graham Bell Professor in Health Care Entrepreneurship at Boston University, acknowledged that most of the attention in the cohorts that would constitute the lung atlas of the cancer interception research team lung is made up of current or previous smokers.
It may be at the risk of pre-malignant adenocarcinoma that investigators may find more cohorts of nonsmokers.
“I believe we have the potential to influence how we diagnose and potentially intercept pre-malignant patients who are nonsmokers with adenocarcinomas,” Spira said.
Sign up and listen to Lungcast on your favorite platforms:
.
[ad_2]
Source link
